Drug Trial Radar · NCT06800313
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Feb 6, 2025
Primary completion
Aug 17, 2028
Study completion Aug 17, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Conditions
- Metastatic Prostate Cancer
Interventions
JNJ-101556143 Formulation 1Drug
Experimental: Oral JNJ-101556143
JNJ-101556143 Formulation 2Drug
Experimental: Oral JNJ-101556143
JNJ-101556143 Formulation 3Drug
Experimental: Oral JNJ-101556143
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of dose-limiting toxicities (DLTs)Time frame: 21 days
- Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baselineTime frame: 21 days
- Phase 1 Part 2 (formulation exploration) relative bioavailabilityTime frame: 22 days
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Center
Colorado Springs, Colorado · Recruiting
Sarah Cannon Research Institute 1
Denver, Colorado · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
XCancer Research Network LCMC Health EJGH
Metairie, Louisiana · Recruiting
Dana Farber Mass General Brigham Cancer Care Inc
Boston, Massachusetts · Recruiting
South Texas Accelerated Research Therapeutics, LLC (START)
Grand Rapids, Michigan · Recruiting
Urology Cancer Center, PC
Omaha, Nebraska · Recruiting
Memorial Sloan Kettering Cancer Center
Long Island City, New York · Recruiting
Associated Medical Professionals
Syracuse, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Urology Associates
Nashville, Tennessee · Recruiting
NEXT Oncology
Austin, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Virginia Clinical Research
Norfolk, Virginia · Recruiting
The Royal Marsden NHS Trust
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.